Abstract
Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid tumors.
Current Drug Targets
Title:Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Volume: 15 Issue: 6
Author(s): Xiaoyang Li, Jian Zhang, Yuanchao Xie, Yuqi Jiang, Zhang Yingjie and Wenfang Xu
Affiliation:
Keywords: Combined therapy, hematologic malignancies, histone deacetylase inhibitors, monotherapy, panobinostat, solid tumors.
Abstract: Histone deacetylases are a class of enzymes that play important roles in post translational modifications of histones by deacetylating the lysine residues as well as interacting with various non-histone proteins. This type of enzymes is closely related to oncogenesis and has been proved to be attractive targets for designing novel anti-cancer agents. Over the last 10 years, a large number of HDACs have entered pre-clinical and/or clinical trials. Among these drug candidates, the pan-HDAC inhibitor, panobinostat demonstrated high therapeutic potential as monotherapy and combined therapy in both preclinical models and clinical cancer patients. In this review, we have mainly focused on the recent progress of the clinical studies about panobinostat, and discussed its anti-cancer effects and molecular rationale for the treatment strategies.
Export Options
About this article
Cite this article as:
Li Xiaoyang, Zhang Jian, Xie Yuanchao, Jiang Yuqi, Yingjie Zhang and Xu Wenfang, Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer, Current Drug Targets 2014; 15 (6) . https://dx.doi.org/10.2174/1389450115666140306152642
DOI https://dx.doi.org/10.2174/1389450115666140306152642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features
Current Angiogenesis (Discontinued) Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Matrine-Family Alkaloids: Versatile Precursors for Bioactive Modifications
Medicinal Chemistry Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Interaction and Structural Modification of Topoisomerase IIα by Peptidyl Prolyl Isomerase, pin1: An In Silico Study
Protein & Peptide Letters The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Edema-mass Ratio Based On Magnetic Resonance Imaging As A Preoperative Diagnostic Factor For Posterior Fossa Metastasis
Current Medical Imaging Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Advancing the Therapeutic Efficacy of Bioactive Molecules by Delivery Vehicle Platforms
Current Medicinal Chemistry Flavonoids: The Innocuous Agents Offering Protection against Alzheimer’s Disease Through Modulation of Proinflammatory and Apoptotic Pathways
Current Topics in Medicinal Chemistry Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design The Use of Naphthoquinones and Furano-naphthoquinones as Antiinvasive Agents
Current Medicinal Chemistry Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Gold Nanostructures as Photothermal Therapy Agent for Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of Shcbp1 in Signaling and Disease
Current Cancer Drug Targets Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry